Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-site, Randomized, Sham-Controlled, Double-Blind Trial With One-Way Crossover Designed to Assess the Effectiveness and Safety of the Gimer NeuroBlock SCS Trialing System for the Treatment of Chronic Back Pain and/or Lower Limb Pain

NCT04693650 is registered in ClinicalTrials.gov with GiMer Medical as lead sponsor.

NCT NCT04693650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04693650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-site, Randomized, Sham-Controlled, Double-Blind Trial With One-Way Crossover Designed to Assess the Effectiveness and Safety of the Gimer NeuroBlock SCS Trialing System for the Treatment of Chronic Back Pain and/or Lower Limb Pain
Lead sponsor
GiMer Medical
Phase
Not applicable
Overall status
Completed
Start date
March 1, 2021
Completion date
April 1, 2022
Enrollment
22 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic pain, low back pain, lower limb pain